In 2022, based on the PSMA-VISION trial, [177Lu]Lu-PSMA-617 (PLUVICTOTM, Novartis AG, Basel, Switzerland) became the first PSMA-directed radiopharmaceutical to be formally approved by the American Food and Drug Administration and the European Medicines Agency for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer who had previously been treated with androgen receptor pathway-inhibiting drugs and taxane-based chemotherapy [11, 12]. The gene discussed is FOLH1; the disease is Familial prostate cancer.